SNY announced that, as part of an ongoing R&D review, amlitelimab will be discontinued in Atopic Dermatitis despite positive results from th
SNY announced that, as part of an ongoing R&D review, amlitelimab will be discontinued in Atopic Dermatitis despite positive results from the ESTURY trial, as the data were not seen as sufficient to represent a meaningful improvement over the standard of Care for patients with Atopic Dermatitis
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.